Clinical Trials | December 27, 2025
IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Subscribe To Our Newsletter & Stay Updated
